Unlock instant, AI-driven research and patent intelligence for your innovation.

Predominant form of neutral endopeptidase inhibitor salt and preparation method thereof

A technology with advantages and forms, applied in the direction of carboxylic acid amide preparation, organic chemical methods, chemical instruments and methods, etc., can solve the problems of unfavorable compound 2 preparation process, optimization, undisclosed preparation methods, etc., and achieve good fluidity and free speed Fast and good solubility effect

Active Publication Date: 2020-06-09
SHENZHEN SALUBRIS PHARMA CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Chinese patent CN200780034141.3 discloses a preparation process route of compound 1 calcium salt, but does not disclose the specific preparation method, and compound 1 calcium salt prepared by conventional methods is a mixed crystal, although it can be used for subsequent production, but It is not conducive to the optimization of the overall preparation process of compound 2

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Predominant form of neutral endopeptidase inhibitor salt and preparation method thereof
  • Predominant form of neutral endopeptidase inhibitor salt and preparation method thereof
  • Predominant form of neutral endopeptidase inhibitor salt and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Preparation of Compound 1(A-3)

[0047]

[0048] Dissolve A-1 (15g) in 150ml of absolute ethanol at room temperature; heat to 60°C, slowly add 8.5ml of thionyl chloride dropwise and then raise the temperature to 70°C for 2 hours; distill under reduced pressure to obtain a white solid, then add 150ml of normal After removing half of the volume of the heptane under reduced pressure, it was beaten in an ice bath for 20 minutes; filtered, the solid was rinsed with n-heptane, and dried at 30°C for 10 hours to obtain 13.4 g of a white solid (A-2).

[0049] Add 13.4g A-2 to a flask containing 250ml isopropyl acetate (IPAC) at room temperature; add 11.7g (16ml) triethylamine and 4.9g succinic anhydride in turn, react at room temperature until A-2 is completely consumed; filter directly , the filter cake was washed with IPAC, and 22 g (A-3) of the light yellow viscous liquid obtained by combining the filtrate was decompressed.

Embodiment 2

[0051] Preparation of Predominant Form of Compound 1 Calcium Salt (A-5)

[0052]

[0053] Dissolve 22g of A-3 prepared according to the method of Example 1 in 200ml of IPAC at room temperature; add 1.2 equivalents (relative to A-2) of sodium hydroxide aqueous solution (1N) dropwise, and stir at room temperature until fully salted; separate and combine Water layer (about 80ml);

[0054] Add the aqueous solution containing A-4 into a 250ml two-necked bottle at room temperature, slowly and uniformly add calcium chloride aqueous solution (3.6g calcium chloride dissolved in 20ml water) dropwise, after 10 minutes, stir at room temperature at a speed of 180r / min for 3 hours ; Filtration, washing the filter cake with water, and drying under reduced pressure at 30° C. for 6 hours to obtain 21 g of the dominant form of compound 1 calcium salt (A-5). After testing, its XRD spectrum is as follows figure 1 As shown, the DSC spectrum is as image 3 As shown, its TG spectrum is shown a...

Embodiment 3

[0056] Preparation of the dominant form of compound 1 calcium salt (A-5).

[0057]

[0058] Dissolve 22g of A-3 prepared according to the method of Example 1 in 200ml of IPAC; add 1.1 equivalent (relative to A-2) sodium hydroxide aqueous solution (1N) dropwise under ice bath, stir at 40°C until fully salted; separate liquids , Merge the water layer; After heating up to 70°C, slowly and uniformly add calcium chloride aqueous solution (3.1g calcium chloride dissolved in 20ml water) dropwise to the aqueous solution containing A-4, after 8 minutes, the temperature is raised to 70°C and the rotation speed is 180r / Stir for 2 hours; cool down to 50°C and filter, wash the filter cake with water and then purging with nitrogen for 1h, and bake under vacuum at 80°C for 48h to obtain 18g of the predominant form of compound 1 calcium salt (A-5) (purity 99.2%). After testing, its XRD spectrum is as follows figure 2 As shown, the DSC spectrum is as image 3 As shown, its TG spectrum i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses advantage forms of compound 1 calcium salt. The effects of quantitative accuracy improvement, synthetic process simplification, production environment optimization and final product quality control are achieved through the advantages on the aspects of fluidity, stability, solubility and the like.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry, and in particular relates to a dominant form of a neutral endopeptidase inhibitor salt and a preparation method thereof. Background technique [0002] Compound 1, a neutral endopeptidase inhibitor (NEPi), has clinical natriuretic and diuretic effects. [0003] [0004] Compound 2 is a drug for anti-heart failure developed by Novartis. This compound is a supramolecular complex (complex) formed by valsartan and compound 1 through non-covalent bonds, and has angiotensin Dual action of receptor blockade and neutral endopeptidase inhibition. The results of completed clinical trials show that compound 2 has a better clinical anti-heart failure effect than enalapril, and is an anti-heart failure drug with great market potential. [0005] [0006] In the disclosed method for synthesizing compound 2, the free acid of compound 1 or the salt of compound 1 can be used as a raw material. However, s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07C233/47C07C231/12C07C231/24
CPCC07B2200/13C07C231/02C07C231/12C07C231/24C07C233/47
Inventor 许文杰华怀杰李松张贵平
Owner SHENZHEN SALUBRIS PHARMA CO LTD